What is William Blair’s Estimate for Neurogene Q1 Earnings?

Neurogene Inc. (NASDAQ:NGNE) – Stock analysts at William Blair issued their Q1 2025 EPS estimates for shares of Neurogene in a research report issued on Tuesday, March 25th. William Blair analyst S. Corwin expects that the company will post earnings of ($0.92) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. William Blair also issued estimates for Neurogene’s Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($3.70) EPS and FY2026 earnings at ($4.60) EPS.

Neurogene (NASDAQ:NGNE) last released its earnings results on Monday, March 24th. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.05. The company had revenue of $0.93 million during the quarter.

Separately, HC Wainwright lowered their target price on Neurogene from $55.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $59.80.

Neurogene Trading Up 13.7 %

Shares of Neurogene stock opened at $16.14 on Thursday. The stock’s fifty day simple moving average is $16.97 and its 200 day simple moving average is $29.06. The company has a market capitalization of $239.76 million, a PE ratio of -3.78 and a beta of 1.01. Neurogene has a 12 month low of $13.47 and a 12 month high of $74.49.

Insider Buying and Selling at Neurogene

In other news, CFO Christine Mikail Cvijic sold 4,501 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $16.94, for a total transaction of $76,246.94. Following the completion of the transaction, the chief financial officer now directly owns 72,343 shares in the company, valued at $1,225,490.42. This represents a 5.86 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 9.92% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NGNE. Samsara BioCapital LLC boosted its holdings in shares of Neurogene by 35.4% in the 4th quarter. Samsara BioCapital LLC now owns 1,717,127 shares of the company’s stock valued at $39,254,000 after buying an additional 449,337 shares during the last quarter. RTW Investments LP lifted its stake in Neurogene by 18.9% in the fourth quarter. RTW Investments LP now owns 1,350,256 shares of the company’s stock valued at $30,867,000 after acquiring an additional 215,000 shares during the last quarter. Redmile Group LLC grew its position in shares of Neurogene by 36.9% in the 4th quarter. Redmile Group LLC now owns 1,319,763 shares of the company’s stock valued at $30,170,000 after acquiring an additional 355,416 shares during the period. Casdin Capital LLC increased its stake in shares of Neurogene by 146.9% during the 4th quarter. Casdin Capital LLC now owns 1,295,361 shares of the company’s stock worth $29,612,000 after purchasing an additional 770,745 shares during the last quarter. Finally, FMR LLC increased its position in Neurogene by 912.4% during the third quarter. FMR LLC now owns 731,801 shares of the company’s stock worth $30,706,000 after buying an additional 659,515 shares during the last quarter. 52.37% of the stock is owned by institutional investors and hedge funds.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.